Letters by company

Amgen INC

1 letter discussing AMGN. Everything written about it on this site is on its ticker page.

Smead Capital Management 3Q25 U.S. Value Strategy Newsletter: Tortoise and the Hare Circa 2025 Smead Capital Management argues that the AI investment boom resembles earlier technology manias and may leave speculative capital spending without adequate returns. The portfolio remains focused on durable businesses in energy, healthcare and homebuilding, where it expects investor capital to rotate as AI enthusiasm fades. 3Q25 EBAY $51B